TRPV3 and keloid: Compounds such as the TRPV1 blocker asivatrep and the TRPV3 inhibitor KM-001 have shown significant antipruritic effects in skin disorders, while tranilast, a TRPV2 antagonist, has provided concrete clinical evidence for TRP modulation in treating keloids.